Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Summary
Third Opinion Trial Synopsis:
This study is trying to see if a combination of three drugs (daratumumab, carfilzomib, and dexamethasone) work better for people with a certain type of cancer (called multiple myeloma) than just two of the drugs (carfilzomib and dexamethasone). They are also trying to figure out if daratumumab works again for people who have already had it before.
This study is trying to see if a combination of three drugs (daratumumab, carfilzomib, and dexamethasone) work better for people with a certain type of cancer (called multiple myeloma) than just two of the drugs (carfilzomib and dexamethasone). They are also trying to figure out if daratumumab works again for people who have already had it before.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously exposed to daratumumab to evaluate daratumumab retreatment.
The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously exposed to daratumumab to evaluate daratumumab retreatment.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.